Shandong Sinobioway Biomedicine Co Ltd Net Assets
Shandong Sinobioway Biomedicine Co Ltd net assets. Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) has net assets worth CN¥1.87 Billion CNY (≈ $273.53 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.05 Billion ≈ $299.29 Million USD) and total liabilities (CN¥176.06 Million ≈ $25.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Shandong Sinobioway Biomedicine Co Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.87 Billion |
| % of Total Assets | 91.39% |
| Annual Growth Rate | 19.08% |
| 5-Year Change | -21.18% |
| 10-Year Change | -22.99% |
| Growth Volatility | 74.3 |
Net Assets of Shandong Sinobioway Biomedicine Co Ltd (2007–2025)
Net assets of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2025. This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's net assets have evolved over time, based on quarterly financial data. See 002581 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2025)
The table below shows the annual net assets of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2025. For live market cap and overall valuation, see how much is Shandong Sinobioway Biomedicine Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.95 Billion ≈ $284.82 Million |
-3.75% |
| 2024-12-31 | CN¥2.02 Billion ≈ $295.93 Million |
-6.97% |
| 2023-12-31 | CN¥2.17 Billion ≈ $318.08 Million |
-11.94% |
| 2022-12-31 | CN¥2.47 Billion ≈ $361.21 Million |
-0.04% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.34 Million |
+12.72% |
| 2020-12-31 | CN¥2.19 Billion ≈ $320.56 Million |
-8.30% |
| 2019-12-31 | CN¥2.39 Billion ≈ $349.56 Million |
-15.29% |
| 2018-12-31 | CN¥2.82 Billion ≈ $412.66 Million |
-3.37% |
| 2017-12-31 | CN¥2.92 Billion ≈ $427.04 Million |
+15.47% |
| 2016-12-31 | CN¥2.53 Billion ≈ $369.84 Million |
+17.89% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.71 Million |
+186.07% |
| 2014-12-31 | CN¥749.40 Million ≈ $109.66 Million |
+1.50% |
| 2013-12-31 | CN¥738.31 Million ≈ $108.04 Million |
+4.81% |
| 2012-12-31 | CN¥704.41 Million ≈ $103.08 Million |
+4.78% |
| 2011-12-31 | CN¥672.28 Million ≈ $98.38 Million |
+279.09% |
| 2010-12-31 | CN¥177.34 Million ≈ $25.95 Million |
+36.73% |
| 2009-12-31 | CN¥129.71 Million ≈ $18.98 Million |
+11.70% |
| 2008-12-31 | CN¥116.12 Million ≈ $16.99 Million |
+38.34% |
| 2007-12-31 | CN¥83.94 Million ≈ $12.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Sinobioway Biomedicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1021.1% over the analyzed period, indicating profitable operations and earnings retention.
Shandong Sinobioway Biomedicine Co Ltd Net Assets Breakdown (December 2025)
Shandong Sinobioway Biomedicine Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥559.27 Million | 30.36% |
| Other Components | CN¥1.28 Billion | 69.64% |
| Total Equity | CN¥1.84 Billion | 100.00% |
Shandong Sinobioway Biomedicine Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Sinobioway Biomedicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Keanda Electronic Techno
SHE:002972
|
$397.79 Million |
|
Wuxi Smart Auto-control Engineering Co Ltd
SHE:002877
|
$397.82 Million |
|
Attica Holdings S.A.
AT:ATTICA
|
$398.00 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
$398.02 Million |
|
InPlay Oil Corp
TO:IPO
|
$397.69 Million |
|
First Carolina Financial Services, Inc.
NYSE:FCBM
|
$397.68 Million |
|
LF Corp
KO:093050
|
$397.56 Million |
|
Zhejiang Jinfei Kaida Wheel Co Ltd
SHE:002863
|
$397.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Sinobioway Biomedicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,923,634,393 to 1,842,213,889, a change of -81,420,504 (-4.2%).
- Net loss of 116,283,662 reduced equity.
- Dividend payments of 1,138,000 reduced retained earnings.
- Other factors increased equity by 36,001,158.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-116.28 Million | -6.31% |
| Dividends Paid | CN¥1.14 Million | -0.06% |
| Other Changes | CN¥36.00 Million | +1.95% |
| Total Change | CN¥- | -4.23% |
Book Value vs Market Value Analysis
This analysis compares Shandong Sinobioway Biomedicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.86x to 1.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.46 | CN¥4.12 | x |
| 2008-12-31 | CN¥0.58 | CN¥4.12 | x |
| 2009-12-31 | CN¥0.61 | CN¥4.12 | x |
| 2010-12-31 | CN¥0.84 | CN¥4.12 | x |
| 2011-12-31 | CN¥2.66 | CN¥4.12 | x |
| 2012-12-31 | CN¥7.41 | CN¥4.12 | x |
| 2013-12-31 | CN¥5.62 | CN¥4.12 | x |
| 2014-12-31 | CN¥5.32 | CN¥4.12 | x |
| 2015-12-31 | CN¥3.16 | CN¥4.12 | x |
| 2016-12-31 | CN¥3.74 | CN¥4.12 | x |
| 2017-12-31 | CN¥4.33 | CN¥4.12 | x |
| 2018-12-31 | CN¥4.17 | CN¥4.12 | x |
| 2019-12-31 | CN¥3.51 | CN¥4.12 | x |
| 2020-12-31 | CN¥3.21 | CN¥4.12 | x |
| 2021-12-31 | CN¥3.62 | CN¥4.12 | x |
| 2022-12-31 | CN¥3.62 | CN¥4.12 | x |
| 2023-12-31 | CN¥3.14 | CN¥4.12 | x |
| 2024-12-31 | CN¥2.92 | CN¥4.12 | x |
| 2025-12-31 | CN¥2.79 | CN¥4.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Sinobioway Biomedicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.31%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.18x
- Recent ROE (-6.31%) is below the historical average (12.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 38.88% | 21.75% | 1.57x | 1.14x | CN¥24.24 Million |
| 2008 | 31.90% | 20.90% | 1.23x | 1.24x | CN¥25.43 Million |
| 2009 | 45.35% | 27.51% | 1.30x | 1.27x | CN¥45.85 Million |
| 2010 | 39.62% | 28.42% | 1.18x | 1.18x | CN¥52.52 Million |
| 2011 | 9.96% | 27.19% | 0.36x | 1.03x | CN¥-251.66K |
| 2012 | 10.47% | 25.66% | 0.39x | 1.03x | CN¥3.34 Million |
| 2013 | 14.82% | 27.27% | 0.52x | 1.05x | CN¥35.55 Million |
| 2014 | 30.03% | 36.04% | 0.81x | 1.03x | CN¥150.07 Million |
| 2015 | 12.00% | 29.16% | 0.36x | 1.16x | CN¥41.78 Million |
| 2016 | 16.91% | 33.02% | 0.47x | 1.09x | CN¥170.75 Million |
| 2017 | 13.60% | 33.41% | 0.29x | 1.40x | CN¥102.75 Million |
| 2018 | -3.77% | -15.61% | 0.15x | 1.56x | CN¥-379.05 Million |
| 2019 | 2.74% | 11.17% | 0.17x | 1.48x | CN¥-167.81 Million |
| 2020 | -9.25% | -70.78% | 0.11x | 1.15x | CN¥-407.66 Million |
| 2021 | 11.35% | 67.29% | 0.15x | 1.15x | CN¥32.18 Million |
| 2022 | -0.62% | -4.11% | 0.12x | 1.20x | CN¥-253.23 Million |
| 2023 | -16.07% | -77.35% | 0.18x | 1.13x | CN¥-539.31 Million |
| 2024 | -7.14% | -38.10% | 0.16x | 1.14x | CN¥-329.68 Million |
| 2025 | -6.31% | -42.31% | 0.13x | 1.18x | CN¥-300.51 Million |
Industry Comparison
This section compares Shandong Sinobioway Biomedicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Sinobioway Biomedicine Co Ltd (002581) | CN¥1.87 Billion | 38.88% | 0.09x | $397.75 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Y… Read more